Radiosensitization of GL261 glioma cells by tetraiodothyroacetic acid (tetrac)

Cell Cycle

Volumn 8, Issue 16, 2009, Pages 2586-2591

  Hercbergs, Aleck ^a   Davis, Paul J ^b   Davis, Faith B ^b   Ciesielski, Michael J ^c   Leith, John T ^d,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Rhode Island Nuclear Science Center   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

Glioblastoma cell growth; Integrin v 3; Potentially lethal damage repair; Sublethal damage repair; Tetrac; Thyroid hormone

Indexed keywords

TETRAIODOTHYROACETIC ACID; THYROXINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL DAMAGE; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; GLIOMA CELL; MOUSE; NONHUMAN; RADIATION INJURY; RADIOSENSITIZATION; X IRRADIATION; X RAY DOSE DISTRIBUTION;

MURINAE;

EID: 69249221537     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.16.9328     Document Type: Article

References (34)

1. Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A, et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 2006; 66:7270-7275 (Pubitemid 44197708)
2. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005; 146:2864-2871 (Pubitemid 41002793)
3. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, et al. L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009; 296:980-991
4. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, et al. Inhibition of αvβ3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11:6270-6279 (Pubitemid 41262958)
5. Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 2008; 29:211-218
6. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 2008; 11:183-190
7. Monferran S, Skuli N, Delmas C, Favre G, Bonnet J, Cohen-Jonathan-Moyal E, et al. αvβ3 and αvβ5 integrins control glioma cell response to ionizing radiation through ILK and SRhoB. Int J Cancer 2008; 123:357-364 (Pubitemid 351842020)
8. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, et al. Propylthiouracilinduced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a Phase I/II study. Anticancer Res 2003; 23:617-626 (Pubitemid 36358462)
9. Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia - a novel paradigm. In Vivo 1996; 10:245-247 (Pubitemid 26169547)
10. Gladson CL. Expression of integrin αvβ3 in small blood vessels of glioblastoma tumors. J Neuropath Experimental Neurol 1996; 55:1143-1149
11. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, et al. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008; 18:378-386 (Pubitemid 351782847)
12. Newcomb EW, Lymberis SC, Lykyanov Y, Shao Y, Schnee T, Devitt M, et al. Radiation sensitivity of GL261 murine glioma model and enhanced radiation sensitivity by flavopiridol. Cell Cycle 2006; 5:93-99
13. Shinohara ET, Cao C, Niemann K, Mu Y, Zeng F, Hallahan DE, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibition. Oncogene 2005; 24:5414-5422 (Pubitemid 43080085)
14. Himmelfarb AJ, Himmelfarb E, Geng I. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63:4009-4016 (Pubitemid 36917920)
15. Schueneman AJ, Himmelfarb E, Geng I, Tan J, Donnelly E, Mendel D, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63:4009-4016 (Pubitemid 36917920)
16. Geng L, Tan J, Himmelfarb E, Schjueneman A, Niermann K, Brousal J, et al. A specific antagonist of the p110delta catalytic subunit of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res 2004; 64:4893-4899 (Pubitemid 38924534)
17. Goldstein A. In: Biostatistics, New York, MacMillan Co 1964; 140-146
18. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, et al. αvβ3/αvβ5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 2009; 69:3308-3316
19. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin αvβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006; 65:1536-1543 (Pubitemid 44425239)
20. Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther 2008; 7:1569-1578
21. Fei P, El-Deiry WS. p53 and radiation response. Oncogene 2003; 22:5774-5783
22. Shih A, Lin HY, Davis FB, Davis PJ. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry 2001; 40:2870-2878 (Pubitemid 32198289)
23. Szatmari T, Lumniczky K, Desaknai S, Trajcevski S, Hidvegi EJ, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006; 97:546-553 (Pubitemid 43811598)
24. Lin HY, Tang HY, Keating T, Wu YN, Shih S, Hammond D, et al. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 2008; 29:62-69 (Pubitemid 351201742)
25. Lin HY, Tang HY, Shih A, Keating T, Cao G, et al. Thyroid hormone is a MAPKdependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 2007; 72:180-187 (Pubitemid 46273502)
26. Yu J, Palmer C, Alenghat T, Li Y, Kao G, Lazar MA. The corepressor silencing mediator for retinoid and thyroid hormone receptor facilitates cellular recovery from DNA double-strand breaks. Cancer Res 2006; 66:9316-9322 (Pubitemid 44521154)
27. Davis PJ, Shih A, Lin HY, Martino LJ, Davis FB. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 2000; 275:38032-38039 (Pubitemid 32004926)
28. Kapiszewska M, Lange CS. The effects of reduced temperature and/or starvation conditions on the radiosensitivity and repair of potentially lethal damage and sublethal damage in L5178Y-R and L5178-S cells. Radiat Res 1988; 113:458-472 (Pubitemid 18079175)
29. + metabolism in health and disease. Trends Biochem Sci 2007; 32:12-19
30. Ben-Hur E, Elkind MM, Bronk BV. Thermally enhanced radioresponse of cultured Chinese hamster cells: inhibition of repair of sublethal damage and enhancement of lethal damage. Radiat Res 1974; 58:38-51.
31. Thraves P, Mossman KL, Brennan T, Dritschilo A. Radiosensitization of human fibroblasts by 3-aminobenzmide: an inhibitor of poly(ADP-ribosylation). Radiat Res 1985; 104:119-127 (Pubitemid 16174841)
32. Burgman P, Konings AWT. Effects of inhibitors of poly(ADP-ribose) polymerase on the radiation response of HeLa S3 cells. Radiat Res 1989; 119:380-386 (Pubitemid 19208567)
33. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, et al. Quantitative PET imaging of tumor integrin αvβ3 expression with 18F-FRGD2. J Nucl Med 2006; 47:113-121
34. Chase GD, Rabinowitz JL. In: Principles of Radioisotope Methodology. Minneapolis MN, Burgess Publ. Co 1962; 68:87-90.